Cell No. : Cell Name
RCB1467 : IP3R^(-) DT40
update : 2024/01/17
|
| Comment | IP3R(type1,type2,type3) deficient DT40 cells |
| Comment from the depositor | |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Kurosaki, Tomohiro
|
| Originator |
Kurosaki, Tomohiro
|
| Year of deposit |
1998
|
| Another name |
R23-11
|
| Original cell |
DT40
|
| Animal |
_avian
< Birds
|
| Tissue |
B cell
|
| Classification |
mutant
|
| Recombinant |
recombinant
|
|
Lifespan |
infinite
|
| Morphology |
lymphocyte-like
|
| Cellosaurus(Expasy) |
CVCL_4634
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Suspension cells
|
| Culture medium |
|
RPMI1640 (4mM Glutamine) + 10% FBS + 1% Chicken serum + 50μM 2-Mercaptoethanol
|
| Culture method |
|
|
| Antibiotics |
|
Free
|
|
Passage method |
|
dilution
|
Culture information
|
Passage cell No |
|
1.5-2 x 10 5 cells/ml
|
| Passage ratio |
|
1 : 20 split
|
| SC frequency |
|
Subculture : every 2 days
|
| Temperature |
|
39.5
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
90% FBS + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma |
|
(-)
|
| Animal PCR |
|
OK
|
| Others |
|
Freezing : 1.0-1.5x10 7 cells/ml/vial. Thawing : 1ml of cells into 20ml media. It is unnecessary to remove DMSO. Pass the next day.
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
2
|
| User's Publication |
9
|
| Reference |
|
2337
Hashimoto A, Okada H, Jiang A, Kurosaki M, Greenberg S, Clark EA, Kurosaki T.
Involvement of guanosine triphosphatases and phospholipase C-gamma2 in extracellular signal-regulated kinase, c-Jun NH2-terminal kinase, and p38 mitogen-activated protein kinase activation by the B cell antigen receptor.
J Exp Med
1998
188(7):1287-95
PubMed ID: 9763608
DOI: 10.1084/jem.188.7.1287
|
|
2281
Sugawara H, Kurosaki M, Takata M, Kurosaki T.
Genetic evidence for involvement of type 1, type 2 and type 3 inositol 1,4,5-trisphosphate receptors in signal transduction through the B-cell antigen receptor.
EMBO J
1997
16(11):3078-88
PubMed ID: 9214625
DOI: 10.1093/emboj/16.11.3078
|
| User's Publication |
|
16819
Horia Vais, Min Wang, Karthik Mallilankaraman, Riley Payne, Chris McKennan, Jeffrey T Lock, Lynn A Spruce, Carly Fiest, Matthew Yan-lok Chan, Ian Parker, Steven H Seeholzer, J Kevin Foskett, Don-On Daniel Mak
ER-luminal [Ca2+] regulation of InsP3 receptor gating mediated by an ER-luminal peripheral Ca2+-binding protein
eLife
2020
9
PubMed ID: 32420875
DOI: 10.7554/elife.53531
|
|
14706
Ren G, Zhou Y, Liang G, Yang B, Yang M, King A, Wei H.
General Anesthetics Regulate Autophagy via Modulating the Inositol 1,4,5-Trisphosphate Receptor: Implications for Dual Effects of Cytoprotection and Cytotoxicity
Sci Rep
2017
7(1):12378
PubMed ID: 28959036
DOI: 10.1038/s41598-017-11607-0
|
|
15634
Rahman T, Taylor CW.
Nuclear patch-clamp recording from inositol 1,4,5-trisphosphate receptors
Methods Cell Biol
2010
99:199-224
PubMed ID: 21035688
DOI: 10.1016/B978-0-12-374841-6.00008-6
|
|
8598
Suzuki J, Yamaguchi K, Kajikawa M, Ichiyanagi K, Adachi N, Koyama H, Takeda S, Okada N.
Genetic evidence that the non-homologous end-joining repair pathway is involved in LINE retrotransposition.
PLoS Genet.
2009
5:e1000461
PubMed ID: 19390601
DOI: 10.1371/journal.pgen.1000461
|
|
9376
Wedel BJ, Vazquez G, McKay RR, St J Bird G, Putney JW Jr.
A calmodulin/inositol 1,4,5-trisphosphate (IP3) receptor-binding region targets TRPC3 to the plasma membrane in a calmodulin/IP3 receptor-independent process.
J. Biol. Chem.
2003
278:25758-65
PubMed ID: 12730194
DOI: 10.1074/jbc.M303890200
|
|
9379
Vazquez G, Wedel BJ, Trebak M, St John Bird G, Putney JW Jr.
Expression level of the canonical transient receptor potential 3 (TRPC3) channel determines its mechanism of activation.
J. Biol. Chem.
2003
278:21649-54
PubMed ID: 12686562
DOI: 10.1074/jbc.M302162200
|
|
9416
Vazquez G, Wedel BJ, Bird GS, Joseph SK, Putney JW.
An inositol 1,4,5-trisphosphate receptor-dependent cation entry pathway in DT40 B lymphocytes.
EMBO J.
2002
21:4531-8
PubMed ID: 12198155
DOI: 10.1093/emboj/cdf467
|
|
9450
Vazquez G, Lievremont JP, St J Bird G, Putney JW Jr.
Human Trp3 forms both inositol trisphosphate receptor-dependent and receptor-independent store-operated cation channels in DT40 avian B lymphocytes.
Proc. Natl. Acad. Sci. U.S.A.
2001
98:11777-82
PubMed ID: 11553786
DOI: 10.1073/pnas.201238198
|
|
9452
Broad LM, Braun FJ, Lievremont JP, Bird GS, Kurosaki T, Putney JW Jr.
Role of the phospholipase C-inositol 1,4,5-trisphosphate pathway in calcium release-activated calcium current and capacitative calcium entry.
J. Biol. Chem.
2001
276:15945-52
PubMed ID: 11278938
DOI: 10.1074/jbc.M011571200
|
Back
Top
CELL BANK Website